Chen Y - Search Results

1

Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC.

Du C, Chen Y, Zhou Y, Zheng D, Zhao J, Tang J, Wu Y, Tu Z. Du C, et al. Among authors: chen y. BMC Cancer. 2023 Dec 21;23(1):1260. doi: 10.1186/s12885-023-11745-x. BMC Cancer. 2023. PMID: 38129808 Free PMC article.

2

Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy.

Zhang YP, Bao ZW, Wu JB, Chen YH, Chen JR, Xie HY, Zhou L, Wu J, Zheng SS. Zhang YP, et al. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820944274. doi: 10.1177/1533033820944274. Technol Cancer Res Treat. 2020. PMID: 32715976 Free PMC article.

3

VIRMA contributes to non-small cell lung cancer progression via N⁶-methyladenosine-dependent DAPK3 post-transcriptional modification.

Xu Y, Chen Y, Yao Y, Xie H, Lu G, Du C, Cheng J, Zhou J. Xu Y, et al. Among authors: chen y. Cancer Lett. 2021 Dec 1;522:142-154. doi: 10.1016/j.canlet.2021.08.027. Epub 2021 Sep 11. Cancer Lett. 2021. PMID: 34520821

4

A robust genomic-based prognostic model for the assessment of cancer stemness and survival for patients with hepatocellular carcinoma.

Du CL, Wei SY, Chen YH, Chen KJ. Du CL, et al. Hepatobiliary Pancreat Dis Int. 2024 Feb;23(1):97-102. doi: 10.1016/j.hbpd.2023.09.002. Epub 2023 Sep 4. Hepatobiliary Pancreat Dis Int. 2024. PMID: 37709605 No abstract available.

5

Cell-free DNA methylation profile potential in the diagnosis of lung squamous cell carcinoma.

Du C, Cai J, Tang J, Chen Y, Díaz-Peña R, Tomita Y, Jassem J, Zhao J, Zheng D, Tu Z. Du C, et al. Among authors: chen y. J Thorac Dis. 2024 Jan 30;16(1):553-563. doi: 10.21037/jtd-23-1827. Epub 2024 Jan 29. J Thorac Dis. 2024. PMID: 38410586 Free PMC article.

6

WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.

Chen Y, Peng C, Chen J, Chen D, Yang B, He B, Hu W, Zhang Y, Liu H, Dai L, Xie H, Zhou L, Wu J, Zheng S. Chen Y, et al. Among authors: chen j, chen d. Mol Cancer. 2019 Aug 22;18(1):127. doi: 10.1186/s12943-019-1053-8. Mol Cancer. 2019. PMID: 31438961 Free PMC article.

7

Activation of YAP1 by N6-Methyladenosine-Modified circCPSF6 Drives Malignancy in Hepatocellular Carcinoma.

Chen Y, Ling Z, Cai X, Xu Y, Lv Z, Man D, Ge J, Yu C, Zhang D, Zhang Y, Xie H, Zhou L, Wu J, Zheng S. Chen Y, et al. Cancer Res. 2022 Feb 15;82(4):599-614. doi: 10.1158/0008-5472.CAN-21-1628. Cancer Res. 2022. PMID: 34916222

8

Efficacy of cytokine-induced killer cell-based immunotherapy for hepatocellular carcinoma.

Jia CC, Chen YH, Cai XR, Li Y, Zheng XF, Yao ZC, Zhao LY, Qiu DB, Xie SJ, Chen WJ, Liu C, Liu QL, Wu XY, Wang TT, Zhang Q. Jia CC, et al. Among authors: chen yh, chen wj. Am J Cancer Res. 2019 Jun 1;9(6):1254-1265. eCollection 2019. Am J Cancer Res. 2019. PMID: 31285957 Free PMC article.

9

ALKBH5 suppresses malignancy of hepatocellular carcinoma via m⁶A-guided epigenetic inhibition of LYPD1.

Chen Y, Zhao Y, Chen J, Peng C, Zhang Y, Tong R, Cheng Q, Yang B, Feng X, Lu Y, Xie H, Zhou L, Wu J, Zheng S. Chen Y, et al. Among authors: chen j. Mol Cancer. 2020 Aug 10;19(1):123. doi: 10.1186/s12943-020-01239-w. Mol Cancer. 2020. PMID: 32772918 Free PMC article.

10

ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.

Chen J, Ding C, Chen Y, Hu W, Yu C, Peng C, Feng X, Cheng Q, Wu W, Lu Y, Xie H, Zhou L, Wu J, Zheng S. Chen J, et al. Among authors: chen y. Cancer Lett. 2021 Apr 1;502:154-165. doi: 10.1016/j.canlet.2020.12.019. Epub 2020 Dec 16. Cancer Lett. 2021. PMID: 33340617

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

177,018 results

Search Page

Filters